[
{"study_indication": "Hypertension", "title": "Effects of Adalat LA 30 mg and Coracten 30 mg on nifedipine plasma concentration , plasma catecholamines, blood pressure response and heart rate in fed mild to moderate hypertensive patients.", "generic_name": "Adalat GITS (Nifedipine, BAYA1040)", "study_id": "100128", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100128_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Cancer", "title": "A phase II multicenter uncontrolled trial of BAY43-9006 in patients with relapsed or refractory advanced non-small cell lung carcinoma", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100557", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100557_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Urinary Tract Infection", "title": "Prospective, open label non-comparative, multi-center trial to evaluate the efficacy and safety of Cipro\u00ae XR 500 mg once daily for 3 days in treating female patients with acute, uncomplicated, symptomatic lower urinary tract infections", "generic_name": "Cipro XR (Ciprofloxacin, BAYO9867)", "study_id": "100546", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100546_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Urinary Tract Infection", "title": "Cipro\u00ae XR Excellence in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections", "generic_name": "Cipro XR (Ciprofloxacin, BAYQ3939)", "study_id": "100544", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100544_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Carcinoma, Hepatocellular", "title": "A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma (SHARP)", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100554", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100554_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A rand, db, parallel-group, plac-controlled study evaluating the efficacy and safety of vardenafil administered for 12 weeks in a flexible-dose regimen compared to plac in men with diabetes mellitus type 1 and erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100540", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100540_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A randomized, double-blind, parallel-group, plac-controlled study evaluating the efficacy and safety of vardenafil administration for 12 weeks in a flexible-dose regimen compared to placebo in men with arterial hypertension and erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100539", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100539_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Maxillary Sinusitis", "title": "Prospective, Multicenter, Open, Uncontrolled Trial to Evaluate the Time to Bacterial eradication and Key Symptom Relief in the treatment of Acute Bacterial Maxillary Sinusitis with Moxifloxacin 400 mg QD (SPEED)", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "100569", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100569_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "An open-label, multi-center, factorial design, cluster-randomized clinical study of vardenafil in Canadian males with Erectile Dysfunction: Impact of education of the primary care physician and patient on patient outcomes.", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100537", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100537_Study_synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "Open-label, multi-centre, study to investigate the safety, tolerability and efficacy of flexible doses of vardenafil given on demand in males with erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100541", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100541_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A randomised, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety, and reliability of 10mg vardenafil administered for 12 weeks compared to placebo in subjects with erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100536", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100536_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Breast Neoplasms", "title": "A phase II multicenter uncontrolled trial of BAY43-9006 in subjects with metastatic breast cancer.", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100555", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100555_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Duration of Efficacy and Safety of Vardenafil Administered for 10 Weeks in a Flexible-Dose Regimen Compared to Placebo in Subjects with Erectile Dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100493", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100493_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A randomized, double blind, parallel group, multi-center study to investigate the efficacy and safety of vardenafil flexible dose versus placebo in males with erectile dysfunction, and their female partners' sexual quality of life.", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100519", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100519_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Placebo in Male Erectile Dysfunction Subjects", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100497", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100497_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "Multi-centre, randomised, double-blind, parallel, placebo-controlled clinical study to assess the efficacy of vardenafil and its influence on self-esteem and self-confidence in patients with erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "11139", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/11139_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Acute Exacerbation Of Chronic Bronchitis", "title": "Concentrations of moxifloxacin in gynecological tissues after single intravenous infusion of 400 mg in patients undergoing elective gynecological surgery (single-dose, randomized, open-label, prospective, single-center study).", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "11134", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/11134_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Pelvic Inflammatory Disease", "title": "Prospective, randomized, double-blind, multicenter, multinational study comparing efficacy and safety of moxifloxacin 400 mg po od for 14 days with ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days in patients with uncomplicated pelvic inflammatory disease (PID) (MAIDEN)", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "10995", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10995_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Venous Thromboembolism", "study_id": "10945", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10945_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Thromboembolism", "title": "Oral Direct Factor Xa Inhibitor BAY 59-7939 in the Prevention of VTE in Patients Undergoing Total Hip Replacement.\nODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial (ODiXaHip)", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "10942", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10942_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Chronic Myelogenous Leukemia", "title": "Open Label Multi-Centric Phase II Study of the Raf Kinase Inhibitor BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec (Imatinib) (ORACLE)", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "10941", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10941_Study_Synopsis_CTP.pdf"]},
{"study_id": "10954", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10954_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Urinary Tract Infections", "title": "EXPRESS: Evaluating Cipro XR Patient Response, Education, Safety, and Satisfaction (EXPRESS)", "generic_name": "Cipro XR (Ciprofloxacin, BAYO9867)", "study_id": "100534", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100534_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Neoplasm", "title": "Extension Program for Bay 43-9006", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "10922", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10922_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Placebo in Male Erectile Dysfunction Subjects", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10898", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10898_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A double-blind \"preferred\" vardenafil dose study of QoL and Functional Outcomes in Males with Erectile Dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10940", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10940_Study_Synopsis_CTP.pdf"]},
{"study_id": "10916", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10916_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A randomized, open-label, multi-center, parallel group study to investigate the efficacy and safety of vardenafil in comparison to tadalafil in males with erectile dysfunction and a diagnosis of diabetes, hypertension or hyperlipidemia (LUTECIA)", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10893", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10893_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Carcinoma, Hepatocellular", "title": "A phase II multicenter uncontrolled trial of Sorafenib (BAY43-9006) in patients with advanced Hepatocellular Carcinoma", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "10874", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10874_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Pneumonia", "title": "A Study of Avelox for Treatment of Elderly Patients with Community Acquired Pneumonia", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "10872", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10872_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Venous Thrombosis", "title": "Randomized, placebo-controlled, parallel-group study in healthy male subjects to investigate the pharmacodynamics during the switching procedure from warfarin to rivaroxaban", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "10849", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10849_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Venous Thromboembolism", "title": "Controlled, Double-Blind, Randomised, Dose-ranging Study on the Prevention of VTE in patients Undergoing Elective Total Hip Replacement- ODIXa-HIP2 Study BAY 59-7939 (ODIXa-HIP2)", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "10944", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10944_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A randomised, double blind, placebo controlled, multi-center, fixed dose, parallel group study to investigate the efficacy and safety of vardenafil (BAY 38-9456) in men with erectile dysfunction .", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10695", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10695_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "An Open-label, Multicenter Study to Assess Safety, Tolerability, Efficacy and Impact on Quality of Life of Vardenafil 10mg in Patients With Erectile Dysfunction Within a Time Window of up to 6 Hours After Intake of Study Drug", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10678", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10678_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A National, multicentre, open label, flexible dose, twelve week treatment to assess the efficacy and safety of 5mg, 10mg and 20mg Bay 38-9456, a Phosphodiesterase Type V inhibitor, in the treatment of male patients with erectile dysfunction (VIS)", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10781", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10781_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "Randomised, double blind, placebo controlled, parallel group, multi-centre, multinational study to evaluate the efficacy and tolerability of Vardenafil (BAY 38-9456) in treatment of male erectile dysfunction in Asia", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10657", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10657_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Bacterial Infections", "title": "A population pharmacokinetics study of plasma levels of ciprofloxacin following a regimen of repeated dose I.V. administration (400 mg TID) on burn patients", "generic_name": "Ciprofloxacin (BAYO9867)", "study_id": "10627", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10627_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A randomized double-blind multi-center parallel group three month study to compare the tolerability and efficacy of flexible dose vardenafil versus placebo in men with depression and erectile dysfunction. (DRIVER)", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10621", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10621_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Diabetes Mellitus", "title": "A multi-centre, parallel, double-blind, randomised and placebo controlled Spanish study, to prevent or delay the development of type 2 diabetes in subjects with impaired glucose homeostasis treated with Acarbose in Primary Care (PREDIAP)", "generic_name": "Acarbose (BAYG5421)", "study_id": "10139", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10139_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "An open, multi-centre, flexible dose uptitration study to investigate the efficacy and safety of vardenafil 10 mg and 20 mg in males with spinal cord injury suffering from erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100608", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100608_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A rand, db, parallel-group, plac-controlled study evaluating the efficacy and safety of vardenafil administered for 12 weeks in a flexible-dose regimen compared to plac in subjects with ED solely secondary to traumatic spinal cord injury", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10473", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10473_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Bacterial Infections", "title": "Prospective, randomized, double-blind, comparison of ciprofloxacin extended-release 1000 mg tablets given as two different prophylactic dosing regimens (Regimen I - Single-dose ciprofloxacin MR 1000 mg or Regimen  II - Multiple-dose ciprofloxacin MR 1000 mg once daily for 3 days) for the prevention of post-operative infectious complications in patients undergoing transrectal needle biopsy of the prostate", "generic_name": "Cipro (Ciprofloxacin, BAYQ3939)", "study_id": "100588", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100588_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A randomized, placebo-controlled, double-blind, multi-centre, parallel group study to investigate the efficacy and safety of BAY 38-9456 in males with diabetes suffering from erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100607", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100607_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "Open-label, multi-centre, study of Levitra 10 mg once a day in males with erectile dysfunction was carried out in four centres namely Lagos, Port Harcourt, Enuge and Maiduguri at their University Teaching Hospitals", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100578", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100578_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "REALISE Levitra\u00ae - Real Life Safety and Efficacy of Levitra (REALISE)", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100477", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100477_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Carcinoma, Renal Cell", "title": "Randomized Discontinuation Study of BAY 43-9006 in patients with Advanced Refractory Cancer.", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100391", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100391_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "Randomized, Double-blind, Multi-centre, Parallel-goup Study to Investigate the Efficacy and Safety of Three Doses of BAY38-9456 (5 mg, 10 mg and 20 mg) Versus Placebo in the Treatment of Patients with Erectile Dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10690", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10690_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Infectious Diseases", "title": "A prospective, open-label, non-randomized, naturalistic, long-term safety surveillance, observational study of either ciprofloxacin (either as oral suspension, oral tablets or sequential IV followed by oral therapy or purely IV therapy) or a non-quinolone antibiotic (either as oral suspension, oral tablets or sequential IV followed by oral therapy or purely IV therapy) in the treatment of pediatric patients with infectious diagnoses", "generic_name": "Ciprofloxacin (BAYQ3939)", "study_id": "100201", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100201_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Carcinoma", "title": "Phase I Study to Determine the Safety, Maximum Tolerated Dose, PK of BAY43-9006 in Repeated Cycles of 18 Days On/3 Days Off in Combination With Paclitaxel and Carboplatin Chemotherapy in Patients With Advanced, Refractory Solid Tumors", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100375", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100375_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A randomized, double blind, double dummy, parallel group, multi-center study to investigate the time to onset of action of 10 mg and 20 mg of vardenafil compared to placebo in males with erectile dysfunction.", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100492", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100492_Study_Synopsis_CTP.pdf"]}
][
{"study_indication": "Hypertension", "title": "Effects of Adalat LA 30 mg and Coracten 30 mg on nifedipine plasma concentration , plasma catecholamines, blood pressure response and heart rate in fed mild to moderate hypertensive patients.", "generic_name": "Adalat GITS (Nifedipine, BAYA1040)", "study_id": "100128", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100128_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Bacterial Infections", "title": "Prospective, randomized, double-blind, comparison of ciprofloxacin extended-release 1000 mg tablets given as two different prophylactic dosing regimens (Regimen I - Single-dose ciprofloxacin MR 1000 mg or Regimen  II - Multiple-dose ciprofloxacin MR 1000 mg once daily for 3 days) for the prevention of post-operative infectious complications in patients undergoing transrectal needle biopsy of the prostate", "generic_name": "Cipro (Ciprofloxacin, BAYQ3939)", "study_id": "100588", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100588_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "Open-label, multi-centre, study of Levitra 10 mg once a day in males with erectile dysfunction was carried out in four centres namely Lagos, Port Harcourt, Enuge and Maiduguri at their University Teaching Hospitals", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100578", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100578_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Breast Neoplasms", "title": "A phase II multicenter uncontrolled trial of BAY43-9006 in subjects with metastatic breast cancer.", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100555", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100555_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Cancer", "title": "A phase II multicenter uncontrolled trial of BAY43-9006 in patients with relapsed or refractory advanced non-small cell lung carcinoma", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100557", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100557_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Carcinoma, Hepatocellular", "title": "A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma (SHARP)", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100554", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100554_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Urinary Tract Infection", "title": "Cipro\u00ae XR Excellence in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections", "generic_name": "Cipro XR (Ciprofloxacin, BAYQ3939)", "study_id": "100544", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100544_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "Open-label, multi-centre, study to investigate the safety, tolerability and efficacy of flexible doses of vardenafil given on demand in males with erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100541", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100541_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Urinary Tract Infection", "title": "Prospective, open label non-comparative, multi-center trial to evaluate the efficacy and safety of Cipro\u00ae XR 500 mg once daily for 3 days in treating female patients with acute, uncomplicated, symptomatic lower urinary tract infections", "generic_name": "Cipro XR (Ciprofloxacin, BAYO9867)", "study_id": "100546", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100546_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A randomized, double-blind, parallel-group, plac-controlled study evaluating the efficacy and safety of vardenafil administration for 12 weeks in a flexible-dose regimen compared to placebo in men with arterial hypertension and erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100539", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100539_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "An open-label, multi-center, factorial design, cluster-randomized clinical study of vardenafil in Canadian males with Erectile Dysfunction: Impact of education of the primary care physician and patient on patient outcomes.", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100537", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100537_Study_synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A randomised, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety, and reliability of 10mg vardenafil administered for 12 weeks compared to placebo in subjects with erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100536", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100536_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A rand, db, parallel-group, plac-controlled study evaluating the efficacy and safety of vardenafil administered for 12 weeks in a flexible-dose regimen compared to plac in men with diabetes mellitus type 1 and erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100540", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100540_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Urinary Tract Infections", "title": "EXPRESS: Evaluating Cipro XR Patient Response, Education, Safety, and Satisfaction (EXPRESS)", "generic_name": "Cipro XR (Ciprofloxacin, BAYO9867)", "study_id": "100534", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100534_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Maxillary Sinusitis", "title": "Prospective, Multicenter, Open, Uncontrolled Trial to Evaluate the Time to Bacterial eradication and Key Symptom Relief in the treatment of Acute Bacterial Maxillary Sinusitis with Moxifloxacin 400 mg QD (SPEED)", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "100569", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100569_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "Multi-centre, randomised, double-blind, parallel, placebo-controlled clinical study to assess the efficacy of vardenafil and its influence on self-esteem and self-confidence in patients with erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "11139", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/11139_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Acute Exacerbation Of Chronic Bronchitis", "title": "Concentrations of moxifloxacin in gynecological tissues after single intravenous infusion of 400 mg in patients undergoing elective gynecological surgery (single-dose, randomized, open-label, prospective, single-center study).", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "11134", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/11134_Study_Synopsis_CTP.pdf"]},
{"study_id": "10954", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10954_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Pelvic Inflammatory Disease", "title": "Prospective, randomized, double-blind, multicenter, multinational study comparing efficacy and safety of moxifloxacin 400 mg po od for 14 days with ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days in patients with uncomplicated pelvic inflammatory disease (PID) (MAIDEN)", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "10995", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10995_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Venous Thromboembolism", "study_id": "10945", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10945_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Venous Thromboembolism", "title": "Controlled, Double-Blind, Randomised, Dose-ranging Study on the Prevention of VTE in patients Undergoing Elective Total Hip Replacement- ODIXa-HIP2 Study BAY 59-7939 (ODIXa-HIP2)", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "10944", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10944_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Thromboembolism", "title": "Oral Direct Factor Xa Inhibitor BAY 59-7939 in the Prevention of VTE in Patients Undergoing Total Hip Replacement.\nODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial (ODiXaHip)", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "10942", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10942_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Chronic Myelogenous Leukemia", "title": "Open Label Multi-Centric Phase II Study of the Raf Kinase Inhibitor BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec (Imatinib) (ORACLE)", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "10941", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10941_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A double-blind \"preferred\" vardenafil dose study of QoL and Functional Outcomes in Males with Erectile Dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10940", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10940_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A randomized, double blind, parallel group, multi-center study to investigate the efficacy and safety of vardenafil flexible dose versus placebo in males with erectile dysfunction, and their female partners' sexual quality of life.", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100519", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100519_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A randomized, open-label, multi-center, parallel group study to investigate the efficacy and safety of vardenafil in comparison to tadalafil in males with erectile dysfunction and a diagnosis of diabetes, hypertension or hyperlipidemia (LUTECIA)", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10893", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10893_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Placebo in Male Erectile Dysfunction Subjects", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10898", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10898_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Neoplasm", "title": "Extension Program for Bay 43-9006", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "10922", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10922_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Carcinoma, Hepatocellular", "title": "A phase II multicenter uncontrolled trial of Sorafenib (BAY43-9006) in patients with advanced Hepatocellular Carcinoma", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "10874", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10874_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Pneumonia", "title": "A Study of Avelox for Treatment of Elderly Patients with Community Acquired Pneumonia", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "10872", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10872_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Venous Thrombosis", "title": "Randomized, placebo-controlled, parallel-group study in healthy male subjects to investigate the pharmacodynamics during the switching procedure from warfarin to rivaroxaban", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "10849", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10849_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A randomised, double blind, placebo controlled, multi-center, fixed dose, parallel group study to investigate the efficacy and safety of vardenafil (BAY 38-9456) in men with erectile dysfunction .", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10695", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10695_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A National, multicentre, open label, flexible dose, twelve week treatment to assess the efficacy and safety of 5mg, 10mg and 20mg Bay 38-9456, a Phosphodiesterase Type V inhibitor, in the treatment of male patients with erectile dysfunction (VIS)", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10781", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10781_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "Randomized, Double-blind, Multi-centre, Parallel-goup Study to Investigate the Efficacy and Safety of Three Doses of BAY38-9456 (5 mg, 10 mg and 20 mg) Versus Placebo in the Treatment of Patients with Erectile Dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10690", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10690_Study_Synopsis_CTP.pdf"]},
{"study_id": "10916", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10916_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "An Open-label, Multicenter Study to Assess Safety, Tolerability, Efficacy and Impact on Quality of Life of Vardenafil 10mg in Patients With Erectile Dysfunction Within a Time Window of up to 6 Hours After Intake of Study Drug", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10678", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10678_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A randomized double-blind multi-center parallel group three month study to compare the tolerability and efficacy of flexible dose vardenafil versus placebo in men with depression and erectile dysfunction. (DRIVER)", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10621", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10621_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "Randomised, double blind, placebo controlled, parallel group, multi-centre, multinational study to evaluate the efficacy and tolerability of Vardenafil (BAY 38-9456) in treatment of male erectile dysfunction in Asia", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10657", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10657_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Diabetes Mellitus", "title": "A multi-centre, parallel, double-blind, randomised and placebo controlled Spanish study, to prevent or delay the development of type 2 diabetes in subjects with impaired glucose homeostasis treated with Acarbose in Primary Care (PREDIAP)", "generic_name": "Acarbose (BAYG5421)", "study_id": "10139", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10139_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "An open, multi-centre, flexible dose uptitration study to investigate the efficacy and safety of vardenafil 10 mg and 20 mg in males with spinal cord injury suffering from erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100608", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100608_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Bacterial Infections", "title": "A population pharmacokinetics study of plasma levels of ciprofloxacin following a regimen of repeated dose I.V. administration (400 mg TID) on burn patients", "generic_name": "Ciprofloxacin (BAYO9867)", "study_id": "10627", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10627_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Placebo in Male Erectile Dysfunction Subjects", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100497", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100497_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A randomized, placebo-controlled, double-blind, multi-centre, parallel group study to investigate the efficacy and safety of BAY 38-9456 in males with diabetes suffering from erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100607", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100607_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A rand, db, parallel-group, plac-controlled study evaluating the efficacy and safety of vardenafil administered for 12 weeks in a flexible-dose regimen compared to plac in subjects with ED solely secondary to traumatic spinal cord injury", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10473", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10473_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Duration of Efficacy and Safety of Vardenafil Administered for 10 Weeks in a Flexible-Dose Regimen Compared to Placebo in Subjects with Erectile Dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100493", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100493_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Carcinoma, Renal Cell", "title": "Randomized Discontinuation Study of BAY 43-9006 in patients with Advanced Refractory Cancer.", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100391", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100391_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "A randomized, double blind, double dummy, parallel group, multi-center study to investigate the time to onset of action of 10 mg and 20 mg of vardenafil compared to placebo in males with erectile dysfunction.", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100492", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100492_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Carcinoma", "title": "Phase I Study to Determine the Safety, Maximum Tolerated Dose, PK of BAY43-9006 in Repeated Cycles of 18 Days On/3 Days Off in Combination With Paclitaxel and Carboplatin Chemotherapy in Patients With Advanced, Refractory Solid Tumors", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100375", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100375_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Infectious Diseases", "title": "A prospective, open-label, non-randomized, naturalistic, long-term safety surveillance, observational study of either ciprofloxacin (either as oral suspension, oral tablets or sequential IV followed by oral therapy or purely IV therapy) or a non-quinolone antibiotic (either as oral suspension, oral tablets or sequential IV followed by oral therapy or purely IV therapy) in the treatment of pediatric patients with infectious diagnoses", "generic_name": "Ciprofloxacin (BAYQ3939)", "study_id": "100201", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100201_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "title": "REALISE Levitra\u00ae - Real Life Safety and Efficacy of Levitra (REALISE)", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100477", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100477_Study_Synopsis_CTP.pdf"]}
][
{"study_indication": "Breast Neoplasms", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100555_Study_Synopsis_CTP.pdf", "path": "full/2342b68317fd9500d6a05c59c61d809d30ac1a2b.pdf", "checksum": "4a847ba96883b5fb3033fb7d80cfae02"}], "title": "A phase II multicenter uncontrolled trial of BAY43-9006 in subjects with metastatic breast cancer.", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100555", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100555_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Carcinoma, Hepatocellular", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100554_Study_Synopsis_CTP.pdf", "path": "full/f6668a2082be546d078ed632583e63b0836d0397.pdf", "checksum": "2ce15fc0bec4e1aa842143d6daabe849"}], "title": "A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma (SHARP)", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100554", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100554_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Hypertension", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100128_Study_Synopsis_CTP.pdf", "path": "full/e3c17d8b80a55605ae66fdb6986a26fcbb40e024.pdf", "checksum": "67d67b67269b8d1931d339df9a125418"}], "title": "Effects of Adalat LA 30 mg and Coracten 30 mg on nifedipine plasma concentration , plasma catecholamines, blood pressure response and heart rate in fed mild to moderate hypertensive patients.", "generic_name": "Adalat GITS (Nifedipine, BAYA1040)", "study_id": "100128", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100128_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Urinary Tract Infection", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100544_Study_Synopsis_CTP.pdf", "path": "full/87a291040077e4d9016e5e10c16476b904bc4acc.pdf", "checksum": "690b98b4d034c0aa2160e05671dc41dc"}], "title": "Cipro\u00ae XR Excellence in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections", "generic_name": "Cipro XR (Ciprofloxacin, BAYQ3939)", "study_id": "100544", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100544_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Urinary Tract Infection", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100546_Study_Synopsis_CTP.pdf", "path": "full/6ca7cd53bba20180d70f906e37d97e56cca35df8.pdf", "checksum": "7c5b1074ffc5d036e63ce74413e6e7f1"}], "title": "Prospective, open label non-comparative, multi-center trial to evaluate the efficacy and safety of Cipro\u00ae XR 500 mg once daily for 3 days in treating female patients with acute, uncomplicated, symptomatic lower urinary tract infections", "generic_name": "Cipro XR (Ciprofloxacin, BAYO9867)", "study_id": "100546", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100546_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Bacterial Infections", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100588_Study_Synopsis_CTP.pdf", "path": "full/b9e46dd9bde3b3d3a79e83e26879a042ecd1a87d.pdf", "checksum": "e732f512f3ce20f8c954ec7d563a75fe"}], "title": "Prospective, randomized, double-blind, comparison of ciprofloxacin extended-release 1000 mg tablets given as two different prophylactic dosing regimens (Regimen I - Single-dose ciprofloxacin MR 1000 mg or Regimen  II - Multiple-dose ciprofloxacin MR 1000 mg once daily for 3 days) for the prevention of post-operative infectious complications in patients undergoing transrectal needle biopsy of the prostate", "generic_name": "Cipro (Ciprofloxacin, BAYQ3939)", "study_id": "100588", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100588_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Cancer", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100557_Study_Synopsis_CTP.pdf", "path": "full/5c33cbc547d864b2fb5a10b00867c52a786e710c.pdf", "checksum": "807ec607c0fd720c36254541f7ce924c"}], "title": "A phase II multicenter uncontrolled trial of BAY43-9006 in patients with relapsed or refractory advanced non-small cell lung carcinoma", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100557", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100557_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100537_Study_synopsis_CTP.pdf", "path": "full/c346a70a512625db4ba674387cf04f2ab63afaff.pdf", "checksum": "37c816ad4f11a95a042358a6218b5fca"}], "title": "An open-label, multi-center, factorial design, cluster-randomized clinical study of vardenafil in Canadian males with Erectile Dysfunction: Impact of education of the primary care physician and patient on patient outcomes.", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100537", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100537_Study_synopsis_CTP.pdf"]},
{"study_indication": "Maxillary Sinusitis", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100569_Study_Synopsis_CTP.pdf", "path": "full/e4a4e14660707e50aae40cb551e618fe4fcc7540.pdf", "checksum": "bc898a3bd639952316ad823eb79935f9"}], "title": "Prospective, Multicenter, Open, Uncontrolled Trial to Evaluate the Time to Bacterial eradication and Key Symptom Relief in the treatment of Acute Bacterial Maxillary Sinusitis with Moxifloxacin 400 mg QD (SPEED)", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "100569", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100569_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100540_Study_Synopsis_CTP.pdf", "path": "full/949db8754b770f3973f1cfea068e019f9e787632.pdf", "checksum": "7c63c2bdc1d4963460c569c87297c9e0"}], "title": "A rand, db, parallel-group, plac-controlled study evaluating the efficacy and safety of vardenafil administered for 12 weeks in a flexible-dose regimen compared to plac in men with diabetes mellitus type 1 and erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100540", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100540_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Urinary Tract Infections", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100534_Study_Synopsis_CTP.pdf", "path": "full/4aecf6789a403cc3c9655212abe6d4a625b85cf6.pdf", "checksum": "cf05a009fe624d034ee3e662ce8c1dca"}], "title": "EXPRESS: Evaluating Cipro XR Patient Response, Education, Safety, and Satisfaction (EXPRESS)", "generic_name": "Cipro XR (Ciprofloxacin, BAYO9867)", "study_id": "100534", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100534_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Acute Exacerbation Of Chronic Bronchitis", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/11134_Study_Synopsis_CTP.pdf", "path": "full/4e80c90597b42811f0bf31a399e82d45fe23ff7a.pdf", "checksum": "0e33b19eb5189d7aa78df8f08cd666ec"}], "title": "Concentrations of moxifloxacin in gynecological tissues after single intravenous infusion of 400 mg in patients undergoing elective gynecological surgery (single-dose, randomized, open-label, prospective, single-center study).", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "11134", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/11134_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100536_Study_Synopsis_CTP.pdf", "path": "full/22b80329f36928f5fdb4a9b9ddcf69a46cc0c0a9.pdf", "checksum": "65e77cfd4afac29066a51dff551ebe6c"}], "title": "A randomised, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety, and reliability of 10mg vardenafil administered for 12 weeks compared to placebo in subjects with erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100536", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100536_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/11139_Study_Synopsis_CTP.pdf", "path": "full/adf4a90e4cad584e829a60e5163c648457f83315.pdf", "checksum": "b950a398f0e81021acf4590b8573163a"}], "title": "Multi-centre, randomised, double-blind, parallel, placebo-controlled clinical study to assess the efficacy of vardenafil and its influence on self-esteem and self-confidence in patients with erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "11139", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/11139_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100519_Study_Synopsis_CTP.pdf", "path": "full/afcb2baa4135c878957d5261d75c174a93555ac5.pdf", "checksum": "4071faeb1c83be753a97d6e161d225b9"}], "title": "A randomized, double blind, parallel group, multi-center study to investigate the efficacy and safety of vardenafil flexible dose versus placebo in males with erectile dysfunction, and their female partners' sexual quality of life.", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100519", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100519_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100578_Study_Synopsis_CTP.pdf", "path": "full/d1d6e02f632273a33f3377b66eca9d643668f04e.pdf", "checksum": "0e476e5a488fa3ee2b391296f13922be"}], "title": "Open-label, multi-centre, study of Levitra 10 mg once a day in males with erectile dysfunction was carried out in four centres namely Lagos, Port Harcourt, Enuge and Maiduguri at their University Teaching Hospitals", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100578", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100578_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Venous Thromboembolism", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10945_Study_Synopsis_CTP.pdf", "path": "full/dc003d5cc8c273bc03a85b1be056ced0579bdd89.pdf", "checksum": "04f908d79d5e0b00ae7cdaff75123b61"}], "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "10945", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10945_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Venous Thromboembolism", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10944_Study_Synopsis_CTP.pdf", "path": "full/cac6ac7628d89de59137017f7549f4629473b60b.pdf", "checksum": "82ce890a9f424bab97c5b297341f5d98"}], "title": "Controlled, Double-Blind, Randomised, Dose-ranging Study on the Prevention of VTE in patients Undergoing Elective Total Hip Replacement- ODIXa-HIP2 Study BAY 59-7939 (ODIXa-HIP2)", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "10944", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10944_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100541_Study_Synopsis_CTP.pdf", "path": "full/f097b564c5f66fe76b2724f8366990892a7588e9.pdf", "checksum": "bf6d365909bdb758b77e8cb6060d8042"}], "title": "Open-label, multi-centre, study to investigate the safety, tolerability and efficacy of flexible doses of vardenafil given on demand in males with erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100541", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100541_Study_Synopsis_CTP.pdf"]},
{"files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10954_Study_Synopsis_CTP.pdf", "path": "full/4b0be2740f3b7d695ce3e763c25026b8fe71bf7c.pdf", "checksum": "0b827d757dd39ab880e5b03de28cbe63"}], "study_id": "10954", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10954_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100539_Study_Synopsis_CTP.pdf", "path": "full/74881f1239074d95204d09d88d7d21a1ef7ce4f6.pdf", "checksum": "08b6e68c19b7044ef29b618e409ea46b"}], "title": "A randomized, double-blind, parallel-group, plac-controlled study evaluating the efficacy and safety of vardenafil administration for 12 weeks in a flexible-dose regimen compared to placebo in men with arterial hypertension and erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100539", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100539_Study_Synopsis_CTP.pdf"]},
{"files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10916_Study_Synopsis_CTP.pdf", "path": "full/dd6c3ab93ced8660cbfb14ae0da1c69ede11f29f.pdf", "checksum": "c2800cab6a9c6ef5e78f1b91bfc2441e"}], "study_id": "10916", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10916_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Thromboembolism", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10942_Study_Synopsis_CTP.pdf", "path": "full/4039c49cd9831899e80019354f893421b3fdc629.pdf", "checksum": "0991e95b88957b0f7d5c2b238f5f14ec"}], "title": "Oral Direct Factor Xa Inhibitor BAY 59-7939 in the Prevention of VTE in Patients Undergoing Total Hip Replacement.\nODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial (ODiXaHip)", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "10942", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10942_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Neoplasm", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10922_Study_Synopsis_CTP.pdf", "path": "full/4737db2fa44151cc6a497c7207df47d86bbaf4df.pdf", "checksum": "0e6e628e44bfaa69c4ec065d423af088"}], "title": "Extension Program for Bay 43-9006", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "10922", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10922_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Chronic Myelogenous Leukemia", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10941_Study_Synopsis_CTP.pdf", "path": "full/4a95494ef75822c59f90ff43b71bfb020ca4bbac.pdf", "checksum": "0e5b80371bd67c9bb89e67159ce2a35b"}], "title": "Open Label Multi-Centric Phase II Study of the Raf Kinase Inhibitor BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec (Imatinib) (ORACLE)", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "10941", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10941_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Carcinoma, Hepatocellular", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10874_Study_Synopsis_CTP.pdf", "path": "full/e92f4c5b43097cef35238f9ce7309af78a14e14a.pdf", "checksum": "1dab8d6d23f76b37b5c8b3fc66b922e0"}], "title": "A phase II multicenter uncontrolled trial of Sorafenib (BAY43-9006) in patients with advanced Hepatocellular Carcinoma", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "10874", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10874_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Pelvic Inflammatory Disease", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10995_Study_Synopsis_CTP.pdf", "path": "full/5470d0d61c351fd0cf8150874c4f64b936fde1b2.pdf", "checksum": "b132c367f5f9c7ff57d3f93cc8d16613"}], "title": "Prospective, randomized, double-blind, multicenter, multinational study comparing efficacy and safety of moxifloxacin 400 mg po od for 14 days with ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days in patients with uncomplicated pelvic inflammatory disease (PID) (MAIDEN)", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "10995", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10995_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10898_Study_Synopsis_CTP.pdf", "path": "full/c72cd13bdc259428cfc2434b6e23628d15943a4f.pdf", "checksum": "a71f2fd6a7977c5530cfed2ab627dd18"}], "title": "A Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Placebo in Male Erectile Dysfunction Subjects", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10898", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10898_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10940_Study_Synopsis_CTP.pdf", "path": "full/cfe60ba9bd280ba0ac36f087da228a55d306faa2.pdf", "checksum": "96b15d8925485a398b22d69627357c24"}], "title": "A double-blind \"preferred\" vardenafil dose study of QoL and Functional Outcomes in Males with Erectile Dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10940", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10940_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Venous Thrombosis", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10849_Study_Synopsis_CTP.pdf", "path": "full/550aea3a387222165c72fa9780e27a225ed8fffd.pdf", "checksum": "49f927472dbf433e8d242495681568ff"}], "title": "Randomized, placebo-controlled, parallel-group study in healthy male subjects to investigate the pharmacodynamics during the switching procedure from warfarin to rivaroxaban", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "10849", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10849_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10893_Study_Synopsis_CTP.pdf", "path": "full/ea5934f4978d392ca5d24b93231c77196afe0513.pdf", "checksum": "799f0a948b1b5a94d2ca8f8737fe7131"}], "title": "A randomized, open-label, multi-center, parallel group study to investigate the efficacy and safety of vardenafil in comparison to tadalafil in males with erectile dysfunction and a diagnosis of diabetes, hypertension or hyperlipidemia (LUTECIA)", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10893", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10893_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10781_Study_Synopsis_CTP.pdf", "path": "full/71c03162f2428a7aac3e97acd214711c6bfcd1aa.pdf", "checksum": "1fd1251e9004bf4e32e4249e6f98c877"}], "title": "A National, multicentre, open label, flexible dose, twelve week treatment to assess the efficacy and safety of 5mg, 10mg and 20mg Bay 38-9456, a Phosphodiesterase Type V inhibitor, in the treatment of male patients with erectile dysfunction (VIS)", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10781", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10781_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10690_Study_Synopsis_CTP.pdf", "path": "full/7069e7a3c0fd432948793b12deeb0b5748770aae.pdf", "checksum": "3249de6da37290e076a790b0f94d16e8"}], "title": "Randomized, Double-blind, Multi-centre, Parallel-goup Study to Investigate the Efficacy and Safety of Three Doses of BAY38-9456 (5 mg, 10 mg and 20 mg) Versus Placebo in the Treatment of Patients with Erectile Dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10690", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10690_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10678_Study_Synopsis_CTP.pdf", "path": "full/a358fb1433f9eac739c6e33cf3697177487e8881.pdf", "checksum": "f2d0d8dd2af770df4bd3e7f494059764"}], "title": "An Open-label, Multicenter Study to Assess Safety, Tolerability, Efficacy and Impact on Quality of Life of Vardenafil 10mg in Patients With Erectile Dysfunction Within a Time Window of up to 6 Hours After Intake of Study Drug", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10678", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10678_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Bacterial Infections", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10627_Study_Synopsis_CTP.pdf", "path": "full/81c5f5a3bec8a40c5382a8393a197de78502e987.pdf", "checksum": "e7ba0fcc0e5b615c64ff7c9f75f6105d"}], "title": "A population pharmacokinetics study of plasma levels of ciprofloxacin following a regimen of repeated dose I.V. administration (400 mg TID) on burn patients", "generic_name": "Ciprofloxacin (BAYO9867)", "study_id": "10627", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10627_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10695_Study_Synopsis_CTP.pdf", "path": "full/88ce30e27e68bfe4e30f946194aa3ed298222e6c.pdf", "checksum": "7bbdb9679c881ce8fb35f294f043a52d"}], "title": "A randomised, double blind, placebo controlled, multi-center, fixed dose, parallel group study to investigate the efficacy and safety of vardenafil (BAY 38-9456) in men with erectile dysfunction .", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10695", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10695_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Pneumonia", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10872_Study_Synopsis_CTP.pdf", "path": "full/82fb7dde6651c4b32ddc07f3340d7383dcf7887c.pdf", "checksum": "9f9f56140bca0a94d39f86ff3b30fa0b"}], "title": "A Study of Avelox for Treatment of Elderly Patients with Community Acquired Pneumonia", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "10872", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10872_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10657_Study_Synopsis_CTP.pdf", "path": "full/17e295bb46a764d0a685427d713fa255643234c7.pdf", "checksum": "a311a798563f0bc428954e25bc60bc71"}], "title": "Randomised, double blind, placebo controlled, parallel group, multi-centre, multinational study to evaluate the efficacy and tolerability of Vardenafil (BAY 38-9456) in treatment of male erectile dysfunction in Asia", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10657", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10657_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10621_Study_Synopsis_CTP.pdf", "path": "full/d651ec1d3f9d55e9fd187bb5bcdb9f1ac54e70d1.pdf", "checksum": "d62ac3e2e09ab68f1f3e24e018a0d2ac"}], "title": "A randomized double-blind multi-center parallel group three month study to compare the tolerability and efficacy of flexible dose vardenafil versus placebo in men with depression and erectile dysfunction. (DRIVER)", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10621", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10621_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10473_Study_Synopsis_CTP.pdf", "path": "full/c1c77d3fdcb89175c7ec13ff62d467088e0e1611.pdf", "checksum": "b1b8af601c258b64d04e58586234ccd0"}], "title": "A rand, db, parallel-group, plac-controlled study evaluating the efficacy and safety of vardenafil administered for 12 weeks in a flexible-dose regimen compared to plac in subjects with ED solely secondary to traumatic spinal cord injury", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10473", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10473_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Diabetes Mellitus", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/10139_Study_Synopsis_CTP.pdf", "path": "full/909ae085b261f6ca654dca1cb83b9c9dd5001a44.pdf", "checksum": "c5f66fa79baba8dd2bc505a127a5fdf0"}], "title": "A multi-centre, parallel, double-blind, randomised and placebo controlled Spanish study, to prevent or delay the development of type 2 diabetes in subjects with impaired glucose homeostasis treated with Acarbose in Primary Care (PREDIAP)", "generic_name": "Acarbose (BAYG5421)", "study_id": "10139", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/10139_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100608_Study_Synopsis_CTP.pdf", "path": "full/42652482ddeab1593dc3be7c3ef57b41dbff015f.pdf", "checksum": "4f6663e0bc08c1c29bc726e3113ab327"}], "title": "An open, multi-centre, flexible dose uptitration study to investigate the efficacy and safety of vardenafil 10 mg and 20 mg in males with spinal cord injury suffering from erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100608", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100608_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100492_Study_Synopsis_CTP.pdf", "path": "full/fbc760f1d2dea0b4fe38d59b31949bf34c0249c5.pdf", "checksum": "d9a080eaea4bba383b09161e452e081a"}], "title": "A randomized, double blind, double dummy, parallel group, multi-center study to investigate the time to onset of action of 10 mg and 20 mg of vardenafil compared to placebo in males with erectile dysfunction.", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100492", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100492_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Carcinoma, Renal Cell", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100391_Study_Synopsis_CTP.pdf", "path": "full/25077f8e756a733926bf672fe4b1a95d3a251aed.pdf", "checksum": "f46e36d12453e892859da331da6b28d7"}], "title": "Randomized Discontinuation Study of BAY 43-9006 in patients with Advanced Refractory Cancer.", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100391", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100391_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100607_Study_Synopsis_CTP.pdf", "path": "full/53b761a0f701e92ceb630540c033f3b54b77e598.pdf", "checksum": "77eaa1a5ed74bfc278590993ced170c9"}], "title": "A randomized, placebo-controlled, double-blind, multi-centre, parallel group study to investigate the efficacy and safety of BAY 38-9456 in males with diabetes suffering from erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100607", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100607_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Carcinoma", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100375_Study_Synopsis_CTP.pdf", "path": "full/a05842344addb5b133eaecf506c079cd561e3aec.pdf", "checksum": "bdb27465a71edd7d41d9a91e4cdfe037"}], "title": "Phase I Study to Determine the Safety, Maximum Tolerated Dose, PK of BAY43-9006 in Repeated Cycles of 18 Days On/3 Days Off in Combination With Paclitaxel and Carboplatin Chemotherapy in Patients With Advanced, Refractory Solid Tumors", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100375", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100375_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100497_Study_Synopsis_CTP.pdf", "path": "full/0e4def3e747eccacc2c6a091a9aac5ebd5a307be.pdf", "checksum": "db3c368bc5e6d0244459ecdb40d27f4b"}], "title": "A Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Placebo in Male Erectile Dysfunction Subjects", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100497", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100497_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Infectious Diseases", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100201_Study_Synopsis_CTP.pdf", "path": "full/b809bcee34c7a5f6c53d957da8bd86ceebe85d17.pdf", "checksum": "8389a189a14d680b1b1c0876a6eec213"}], "title": "A prospective, open-label, non-randomized, naturalistic, long-term safety surveillance, observational study of either ciprofloxacin (either as oral suspension, oral tablets or sequential IV followed by oral therapy or purely IV therapy) or a non-quinolone antibiotic (either as oral suspension, oral tablets or sequential IV followed by oral therapy or purely IV therapy) in the treatment of pediatric patients with infectious diagnoses", "generic_name": "Ciprofloxacin (BAYQ3939)", "study_id": "100201", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100201_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100493_Study_Synopsis_CTP.pdf", "path": "full/23bfc5705bca8feba8bce4ada3f5aeb386bc8890.pdf", "checksum": "4333a097a604ccd1aa169e987727ff7b"}], "title": "A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Duration of Efficacy and Safety of Vardenafil Administered for 10 Weeks in a Flexible-Dose Regimen Compared to Placebo in Subjects with Erectile Dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100493", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100493_Study_Synopsis_CTP.pdf"]},
{"study_indication": "Erectile Dysfunction", "files": [{"url": "http://trialfinder.pharma.bayer.com/omr/online/100477_Study_Synopsis_CTP.pdf", "path": "full/c901aec708a8878c2bc2bb8264a078289f2a49be.pdf", "checksum": "98032a0396e8fd975e6a217fb271ad05"}], "title": "REALISE Levitra\u00ae - Real Life Safety and Efficacy of Levitra (REALISE)", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100477", "sponsor": "Bayer", "file_urls": ["http://trialfinder.pharma.bayer.com/omr/online/100477_Study_Synopsis_CTP.pdf"]}
][
[
{"study_indication": "Hypertension", "files": [], "title": "Effects of Adalat LA 30 mg and Coracten 30 mg on nifedipine plasma concentration , plasma catecholamines, blood pressure response and heart rate in fed mild to moderate hypertensive patients.", "generic_name": "Adalat GITS (Nifedipine, BAYA1040)", "study_id": "100128", "sponsor": "Bayer"},
{"study_indication": "Breast Neoplasms", "files": [], "title": "A phase II multicenter uncontrolled trial of BAY43-9006 in subjects with metastatic breast cancer.", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100555", "sponsor": "Bayer"},
{"study_indication": "Bacterial Infections", "files": [], "title": "Prospective, randomized, double-blind, comparison of ciprofloxacin extended-release 1000 mg tablets given as two different prophylactic dosing regimens (Regimen I - Single-dose ciprofloxacin MR 1000 mg or Regimen  II - Multiple-dose ciprofloxacin MR 1000 mg once daily for 3 days) for the prevention of post-operative infectious complications in patients undergoing transrectal needle biopsy of the prostate", "generic_name": "Cipro (Ciprofloxacin, BAYQ3939)", "study_id": "100588", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "Open-label, multi-centre, study of Levitra 10 mg once a day in males with erectile dysfunction was carried out in four centres namely Lagos, Port Harcourt, Enuge and Maiduguri at their University Teaching Hospitals", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100578", "sponsor": "Bayer"},
{"study_indication": "Cancer", "files": [], "title": "A phase II multicenter uncontrolled trial of BAY43-9006 in patients with relapsed or refractory advanced non-small cell lung carcinoma", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100557", "sponsor": "Bayer"},
{"study_indication": "Urinary Tract Infection", "files": [], "title": "Prospective, open label non-comparative, multi-center trial to evaluate the efficacy and safety of Cipro\u00ae XR 500 mg once daily for 3 days in treating female patients with acute, uncomplicated, symptomatic lower urinary tract infections", "generic_name": "Cipro XR (Ciprofloxacin, BAYO9867)", "study_id": "100546", "sponsor": "Bayer"},
{"study_indication": "Carcinoma, Hepatocellular", "files": [], "title": "A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma (SHARP)", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "100554", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "Open-label, multi-centre, study to investigate the safety, tolerability and efficacy of flexible doses of vardenafil given on demand in males with erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100541", "sponsor": "Bayer"},
{"study_indication": "Urinary Tract Infection", "files": [], "title": "Cipro\u00ae XR Excellence in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections", "generic_name": "Cipro XR (Ciprofloxacin, BAYQ3939)", "study_id": "100544", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "A randomized, double-blind, parallel-group, plac-controlled study evaluating the efficacy and safety of vardenafil administration for 12 weeks in a flexible-dose regimen compared to placebo in men with arterial hypertension and erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100539", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "An open-label, multi-center, factorial design, cluster-randomized clinical study of vardenafil in Canadian males with Erectile Dysfunction: Impact of education of the primary care physician and patient on patient outcomes.", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100537", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "A randomised, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety, and reliability of 10mg vardenafil administered for 12 weeks compared to placebo in subjects with erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100536", "sponsor": "Bayer"},
{"study_indication": "Urinary Tract Infections", "files": [], "title": "EXPRESS: Evaluating Cipro XR Patient Response, Education, Safety, and Satisfaction (EXPRESS)", "generic_name": "Cipro XR (Ciprofloxacin, BAYO9867)", "study_id": "100534", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "A rand, db, parallel-group, plac-controlled study evaluating the efficacy and safety of vardenafil administered for 12 weeks in a flexible-dose regimen compared to plac in men with diabetes mellitus type 1 and erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100540", "sponsor": "Bayer"},
{"study_indication": "Maxillary Sinusitis", "files": [], "title": "Prospective, Multicenter, Open, Uncontrolled Trial to Evaluate the Time to Bacterial eradication and Key Symptom Relief in the treatment of Acute Bacterial Maxillary Sinusitis with Moxifloxacin 400 mg QD (SPEED)", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "100569", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "Multi-centre, randomised, double-blind, parallel, placebo-controlled clinical study to assess the efficacy of vardenafil and its influence on self-esteem and self-confidence in patients with erectile dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "11139", "sponsor": "Bayer"},
{"study_indication": "Pelvic Inflammatory Disease", "files": [], "title": "Prospective, randomized, double-blind, multicenter, multinational study comparing efficacy and safety of moxifloxacin 400 mg po od for 14 days with ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days in patients with uncomplicated pelvic inflammatory disease (PID) (MAIDEN)", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "10995", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "A randomized, double blind, parallel group, multi-center study to investigate the efficacy and safety of vardenafil flexible dose versus placebo in males with erectile dysfunction, and their female partners' sexual quality of life.", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "100519", "sponsor": "Bayer"},
{"files": [], "study_id": "10954", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "sponsor": "Bayer"},
{"study_indication": "Venous Thromboembolism", "study_id": "10945", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "sponsor": "Bayer", "files": []},
{"study_indication": "Acute Exacerbation Of Chronic Bronchitis", "files": [], "title": "Concentrations of moxifloxacin in gynecological tissues after single intravenous infusion of 400 mg in patients undergoing elective gynecological surgery (single-dose, randomized, open-label, prospective, single-center study).", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "11134", "sponsor": "Bayer"},
{"study_indication": "Thromboembolism", "files": [], "title": "Oral Direct Factor Xa Inhibitor BAY 59-7939 in the Prevention of VTE in Patients Undergoing Total Hip Replacement.\nODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial (ODiXaHip)", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "10942", "sponsor": "Bayer"},
{"study_indication": "Chronic Myelogenous Leukemia", "files": [], "title": "Open Label Multi-Centric Phase II Study of the Raf Kinase Inhibitor BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec (Imatinib) (ORACLE)", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "10941", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "A double-blind \"preferred\" vardenafil dose study of QoL and Functional Outcomes in Males with Erectile Dysfunction", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10940", "sponsor": "Bayer"},
{"study_indication": "Venous Thromboembolism", "files": [], "title": "Controlled, Double-Blind, Randomised, Dose-ranging Study on the Prevention of VTE in patients Undergoing Elective Total Hip Replacement- ODIXa-HIP2 Study BAY 59-7939 (ODIXa-HIP2)", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "10944", "sponsor": "Bayer"},
{"files": [], "study_id": "10916", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "A Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Placebo in Male Erectile Dysfunction Subjects", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10898", "sponsor": "Bayer"},
{"study_indication": "Neoplasm", "files": [], "title": "Extension Program for Bay 43-9006", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "10922", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "A randomized, open-label, multi-center, parallel group study to investigate the efficacy and safety of vardenafil in comparison to tadalafil in males with erectile dysfunction and a diagnosis of diabetes, hypertension or hyperlipidemia (LUTECIA)", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "10893", "sponsor": "Bayer"},
{"study_indication": "Pneumonia", "files": [], "title": "A Study of Avelox for Treatment of Elderly Patients with Community Acquired Pneumonia", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "10872", "sponsor": "Bayer"},
{"study_indication": "Carcinoma, Hepatocellular", "files": [], "title": "A phase II multicenter uncontrolled trial of Sorafenib (BAY43-9006) in patients with advanced Hepatocellular Carcinoma", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "10874", "sponsor": "Bayer"},
{"study_indication": "Venous Thrombosis", "files": [], "title": "Randomized, placebo-controlled, parallel-group study in healthy male subjects to investigate the pharmacodynamics during the switching procedure from warfarin to rivaroxaban", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "10849", "sponsor": "Bayer"},
{"study_indication": "Melanoma", "files": [], "title": "Phase II Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination with Dacarbazine (DTIC) Chemotherapy in Subjects with Unresectable Stage III or Stage IV Melanoma", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "11715", "sponsor": "Bayer"},
{"study_indication": "Pulmonary Embolism", "files": [], "title": "Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "11702b", "sponsor": "Bayer"},
{"study_indication": "Venous Thrombosis", "files": [], "title": "Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "11702a", "sponsor": "Bayer"},
{"study_indication": "Blood Loss, Surgical", "files": [], "title": "A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement Surgery", "generic_name": "Trasylol (Aprotinin, BAYA0128)", "study_id": "11694", "sponsor": "Bayer"},
{"study_indication": "Urinary Tract Infection", "files": [], "title": "Efficacy and safety of Ciprofloxacin Extended-Release 1000 mg once-daily versus Ciprofloxacin Immediate-Release 500 mg twice-daily given 7-14 days in patients with Complicated Urinary Tract Infections: prospective, randomized, double-blind trial. (EMERON)", "generic_name": "Cipro XR (Ciprofloxacin, BAYQ3939)", "study_id": "11454", "sponsor": "Bayer"},
{"study_indication": "Infection, intra-abdominal", "files": [], "title": "A prospective, randomized, double-blinded, multi-center trial assessing the safety and efficacy of intravenous administration BAY12-8039 (Moxifloxacin) 400mg every 24 h compared to intravenous ceftriaxone 2g every 24h and metronidazole 500mg every 12h for the treatment of patients with complicated intra-abdominal infections (DRAGON)", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "11647", "sponsor": "Bayer"},
{"study_indication": "Neoplasm", "files": [], "title": "Open label, Phase I study to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics, and biomarker status of BAY73-4506 in patients with advanced malignancies", "generic_name": "Stivarga (Regorafenib, BAY73-4506)", "study_id": "11651", "sponsor": "Bayer"},
{"study_indication": "Atrial fibrillation", "files": [], "title": "A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) with Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "11630", "sponsor": "Bayer"},
{"study_indication": "Colorectal Neoplasms", "files": [], "title": "Phase I, open-label, non-placebo controlled study to determine the safety, pharmacokinetics, and pharmacodynamics of BAY73-4506 in combination with mFOLFOX6 or FOLFIRI as first or second line therapy in patients with metastatic colorectal.", "generic_name": "Stivarga (Regorafenib, BAY73-4506)", "study_id": "11656", "sponsor": "Bayer"},
{"study_indication": "Heart Failure", "files": [], "title": "Proof of concept study to investigate the impact of BAY 58-2667 given intravenously in patients with acute decompensated chronic congestive heart failure", "generic_name": "Cinaciguat (BAY58-2667)", "study_id": "11615", "sponsor": "Bayer"},
{"study_indication": "Intraabdominal Infections", "files": [], "title": "A randomized, double-blind, multicenter trial to evaluate the safety and efficacy of sequential (intravenous, oral) moxifloxacin versus comparator in pediatric subjects with complicated intra-abdominal infection (MOXIPEDIA)", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "11643", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "Randomized, open-label, two-fold crossover study to investigate\nthe relative bioavailability of a 10 mg vardenafil oral\ndisintegrating tablet in comparison to a 10 mg vardenafil standard\ntablet after single oral dosing in healthy male subjects", "generic_name": "Vardenafil ODT (BAY38-9456)", "study_id": "11599", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "A pilot, randomized, double-blind, placebo-controlled, crossover study evaluating the efficacy and safety of vardenafil versus placebo administered 12, 18 and 24 hours prior to initiation of sexual intercourse in subjects with ED", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "11586", "sponsor": "Bayer"},
{"study_indication": "Carcinoma, Renal Cell", "files": [], "title": "Extension study for BAY43-9006 in Japanese patients with Renal cell carcinoma", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "12056", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "A randomized, double-blind, crossover study to evaluate the duration of erection following vardenafil (10mg) administration for four weeks in a fixed dose regimen compared to placebo in males with ED", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "11575", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "Randomized study with a 4-way crossover, single-dose design in\nstage I to investigate the pharmacokinetics of two 20 mg\nvardenafil extended-release tablet formulations in the fed and\nfasted condition in healthy male subjects followed by a\nsubsequent stage II with multiple-dose, placebo-controlled\ncomparison design to investigate the pharmacokinetics, safety,\nand tolerability of once-daily administration of one of these\nformulations in healthy male and female subjects", "generic_name": "Vardenafil ER (BAY38-9456)", "study_id": "12153", "sponsor": "Bayer"},
{"study_indication": "Sexual Dysfunction", "files": [], "title": "A randomized, double blind, parallel group study of vardenafil flexible dose versus placebo in males with erectile dysfunction and their female partners sexual quality of life. PARTNER II", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "12146", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "A randomized, double-blind, placebo-controlled, parallel-group, study evaluating the efficacy, safety, and duration of erection of flexible-dose vardenafil administered for 12 weeks compared to placebo in subjects with erectile dysfunction and dyslipidemia.", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "12165", "sponsor": "Bayer"},
{"study_indication": "Hypertension, Pulmonary", "files": [], "title": "A multicenter, non-randomized, non-blinded, noncontrolled study to investigate the impact of multiple doses of BAY 63-2521 on safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with pulmonary hypertension in a 12-week 3 times a day individual dose titration scheme", "generic_name": "Adempas (Riociguat, BAY63-2521)", "study_id": "12166", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "Pivotal phase III trial to investigate the efficacy and safety of an Orodispersible Tablet vardenafil versus placebo in the treatment of men with Erectile dysfunction (ED) - a fixed-dose, double-blind, randomized multi-center Trial", "generic_name": "Vardenafil ODT (BAY38-9456)", "study_id": "12094", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "Pivotal phase III trial to investigate the efficacy and safety of an Orodispersible Tablet vardenafil versus placebo in the treatment of men with Erectile dysfunction (ED) - a fixed-dose, double-blind, randomized multi-center Trial - POTENT I", "generic_name": "Vardenafil ODT (BAY38-9456)", "study_id": "12093", "sponsor": "Bayer"},
{"study_indication": "Constipation", "files": [], "title": "A double-blind, randomized, uninational, multicenter, two parallel groups, active controlled study to compare the effect of the treatment with Transipeg 2.95 g or Forlax Junior 4 g in children with constipation", "generic_name": "Transipeg (Macrogol, BAY81-8430)", "study_id": "12052", "sponsor": "Bayer"},
{"study_indication": "Hemophilia A", "files": [], "title": "Assessment of the risk of inhibitor formation in subjects with severe hemophilia A when switched from a replacement therapy with a rFVIII produced by a Chinese Hamster Ovary (CHO) cell line to a rFVIII produced by a Baby Hamster Kidney (BHK) cell line (Kogenate\u00ae FS).", "generic_name": "Kogenate FS (Recombinant Factor VIII, BAY14-2222)", "study_id": "12112", "sponsor": "Bayer"},
{"study_indication": "Tinnitus", "files": [], "title": "Evaluation of vardenafil for the treatment of subjective tinnitus: A controlled pilot study", "generic_name": "Levitra (Vardenafil, BAY38-9456)", "study_id": "12049", "sponsor": "Bayer"},
{"study_indication": "Skin Abnormalities", "files": [], "title": "Evaluation of the moisturizing effect of Bepanthen burn relief foam spray new formula versus Bepanthen burn relief foam spray (current formula). Equivalence trial. Intra-individual design.", "generic_name": "Dexpanthenol (BAY81-2996)", "study_id": "12040", "sponsor": "Bayer"},
{"study_indication": "Erythema", "files": [], "title": "Evaluation of the effect of Bepanthen burn relief foam spray new formula on a thermic erythema. Equivalence trial. Intra-individual design.", "generic_name": "Dexpanthenol (BAY81-2996)", "study_id": "12039", "sponsor": "Bayer"},
{"study_indication": "Pain", "files": [], "title": "Randomized, open-label, six-fold cross-over study to investigate\nthe pharmacodynamic effect on thrombocytes and the safety,\ntolerability and pharmacokinetics of acetylsalicylic acid after\nsingle intravenous doses of BAY 81-8781 and oral doses of\nAspirin plain tablets in 24 healthy male and female subjects", "generic_name": "Aspirin (Acetylsalicylic Acid, BAY81-8781)", "study_id": "12011", "sponsor": "Bayer"},
{"study_indication": "Carcinoma, Renal Cell", "files": [], "title": "A Phase II, Multi-centre, Open-label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Renal Cell Carcinoma.", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "12913", "sponsor": "Bayer"},
{"study_indication": "Ovarian neoplasms", "files": [], "title": "A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a Complete Clinical Response after Standard Platinum/Taxane Containing Chemotherapy", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "12007", "sponsor": "Bayer"},
{"study_indication": "Atrial fibrillation", "files": [], "title": "BAY 59-7939 (Factor Xa inhibitor) Phase II low dose study in patients with atrial fibrillation", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "12024", "sponsor": "Bayer"},
{"study_indication": "Hemophilia A", "files": [], "title": "A diagnostic interventional, controlled, cross-sectional evaluation of joint status using Magnetic Resonance Imaging in subjects with severe hemophilia A treated with primary prophylaxis, secondary prophylaxis, or on-demand therapy", "generic_name": "No Drug", "study_id": "12948", "sponsor": "Bayer"},
{"study_indication": "Carcinoma, Hepatocellular", "files": [], "title": "A Phase II randomized, double-blind, placebo-controlled study of sorafenib or placebo in combination with transarterial chemoembolization (TACE) performed with DC Bead and doxorubicin for intermediate stage hepatocellular carcinoma (HCC).", "generic_name": "Nexavar (Sorafenib, BAY43-9006)", "study_id": "12918", "sponsor": "Bayer"},
{"study_indication": "Hypertension, Pulmonary", "files": [], "title": "Proof of concept study to investigate safety, tolerability, pharmacokinetics and the impact on pulmonary and systemic hemodynamics, gas exchange and lung function parameters of a single-dose of BAY63-2521 IR-tablet in patients with COPD associated pulmonary hypertension in an non-randomized, non-blinded design", "generic_name": "Adempas (Riociguat, BAY63-2521)", "study_id": "12915", "sponsor": "Bayer"},
{"study_indication": "Acute Coronary Syndrome", "files": [], "title": "A prospective, randomized, verum controlled, open label, parallel group multi-center phase III clinical trial to demonstrate the superiority of 500 or 250 mg Aspirin\u00ae i.v. (BAY 81-8781) treatment versus 300 mg Aspirin\u00ae N tablets p.o. (BAY e4465A) in patients with Acute Coronary Syndrome, measured by time dependent thromboxane inhibition (ACUTE)", "generic_name": "Aspirin (Acetylsalicylic Acid, BAY81-8781)", "study_id": "12946", "sponsor": "Bayer"},
{"study_indication": "Pulmonary Hypertension", "files": [], "title": "Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH) (PATENT-1)", "generic_name": "Adempas (Riociguat, BAY63-2521)", "study_id": "12934", "sponsor": "Bayer"},
{"study_indication": "Venous Thrombosis", "files": [], "title": "Single-dose pilot study of oral rivaroxaban in pediatric subjects with venous thromboembolism", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "12892", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "Randomized study in a 3-fold crossover, single-dose design to\ninvestigate the pharmacokinetics of a 20 mg vardenafil extended\nrelease pellet formulation in the fed and fasted condition,\nrespectively, in comparison to a 20 mg standard Levitra\u00ae tablet\nin healthy male subjects", "generic_name": "Vardenafil ER (BAY38-9456)", "study_id": "12905", "sponsor": "Bayer"},
{"study_indication": "Neoplasms", "files": [], "title": "Phase Ib trial of the combination of PI3K inhibitor Copanlisib and allosteric-MEK inhibitor Copanlisib in subjects with advanced cancer", "generic_name": "Copanlisib (BAY80-6946)", "study_id": "12876", "sponsor": "Bayer"},
{"study_indication": "Venous Thromboembolism", "files": [], "title": "Multicenter, randomized, parallel-group efficacy and safety study for the prevention of venous thromboembolism in hospitalized medically ill patients comparing rivaroxaban with enoxaparin.\nThe MAGELLAN Study (MAGELLAN)", "generic_name": "Xarelto (Rivaroxaban, BAY59-7939)", "study_id": "12839", "sponsor": "Bayer"},
{"study_indication": "Acute Bacterial Sinusitis", "files": [], "title": "Treatment of patients with acute sinusitis in daily practice", "generic_name": "Avelox (Moxifloxacin, BAY12-8039)", "study_id": "12803", "sponsor": "Bayer"},
{"study_indication": "Erectile Dysfunction", "files": [], "title": "Randomized, double-blind, placebo-controlled study with a\n2-way crossover design in stage I to investigate the incidence of\nthe adverse event heartburn following repeated administration of\n20 mg vardenafil extended release tablets in healthy female and\nmale subjects followed by a subsequent stage II with randomized,\ndouble-blind, 3-way crossover, multiple-dose design of\nvardenafil extended release tablets with and without tartaric acid\ncompared to tartaric acid alone to investigate the tolerability in\nthe same study population", "generic_name": "Vardenafil ER (BAY38-9456)", "study_id": "12826", "sponsor": "Bayer"}